The "addition" and "subtraction" of adjuvant chemotherapy for locally advanced colorectal cancer: where to go next?  

作　　者：Xin-Hua Chen Zhou-Sheng Lin Jiang Yu 

机构地区：[1]Department of General Surgery,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China [2]The Second Clinical Medical School,Southern Medical University,Guangzhou,Guangdong 510515,China

出　　处：《Chinese Medical Journal》2019年第20期2485-2488,共4页中华医学杂志（英文版）

基　　金：grants from the National Natural Science Foundation of China(No.81872013);the National Key Research and Development Program(No.2017YFC0108300);the Science and Technology Planning Project of Guangdong Province(No.2017B020226005);the National Clinical Key Specialty Construction Project(No.[2012]121).

摘　　要：Compared with surgery alone, post-operative adjuvant chemotherapy (ACT) for local colorectal cancer (CRC) can significantly improve survival.[1,2] The benefit of adjuvant fluorouracil (5-FU)-based chemotherapy in stage III CRC was established in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol C-01 trial[3] and consolidated in subsequent studies.

关 键 词：CHEMOTHERAPY ADJUVANT COLORECTAL 

分 类 号：R73[医药卫生—肿瘤]